Molecular imaging using PET for breast cancer

被引：17

作者：

Kurihara, Hiroaki ^{[1
]}

Shimizu, Chikako ^{[2
]}

Miyakita, Yasuji ^{[3
]}

Yoshida, Masayuki ^{[4
]}

Hamada, Akinobu ^{[5
]}

Kanayama, Yousuke ^{[6
]}

Yonemori, Kan ^{[2
]}

Hashimoto, Jun ^{[2
]}

Tani, Hitomi ^{[1
]}

Kodaira, Makoto ^{[2
]}

Yunokawa, Mayu ^{[2
]}

Yamamoto, Harukaze ^{[2
]}

Watanabe, Yasuyoshi ^{[6
]}

Fujiwara, Yasuhiro ^{[2
]}

Tamura, Kenji ^{[2
]}

机构：

[1] Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo 1040045, Japan

[3] Natl Canc Ctr, Dept Neurosurg, Tokyo 1040045, Japan

[4] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo 1040045, Japan

[5] Natl Canc Ctr, Res Inst, Dept Clin Pharmacol Grp, Translat Res Support Core, Tokyo 104, Japan

[6] RIKEN, Ctr Mol Imaging Sci, Kobe, Hyogo, Japan

来源：

BREAST CANCER | 2016年 / 23卷 / 01期

关键词：

Breast cancer; PET; Molecular imaging; Molecular target therapy; HER2; POSITRON-EMISSION-TOMOGRAPHY; ESTROGEN-RECEPTOR; FDG-PET; WHOLE-BODY; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; F-18-FDG PET; TRASTUZUMAB; TUMOR; EXPRESSION;

D O I：

10.1007/s12282-015-0613-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular imaging can visualize the biological processes at the molecular and cellular levels in vivo using certain tracers for specific molecular targets. Molecular imaging of breast cancer can be performed with various imaging modalities, however, positron emission tomography (PET) is a sensitive and non-invasive molecular imaging technology and this review will focus on PET molecular imaging of breast cancer, such as FDG-PET, FLT-PET, hormone receptor PET, and anti-HER2 PET.

引用

页码：24 / 32

页数：9

共 80 条

[1] MRI of tumor angiogenesis [J].

Barrett, Tristan ;

Brechbiel, Martin ;

Bernardo, Marcelino ;

Choyke, Peter L. .

JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 26 (02) :235-249

[2] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[3] Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET [J].

Beer, Ambros J. ;

Niemeyer, Markus ;

Carlsen, Janette ;

Sarbia, Mario ;

Naehrig, Joerg ;

Watzlowik, Petra ;

Wester, Hans-Juergen ;

Harbeck, Nadia ;

Schwaiger, Markus .

JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (02) :255-259

[4] Imaging in breast cancer:: Single-photon computed tomography and positron-emission tomography [J].

Bénard, F ;

Turcotte, É .

BREAST CANCER RESEARCH, 2005, 7 (04) :153-162

[5] Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas [J].

Bhattacharyya, Sibaprasad ;

Kurdziel, Karen ;

Wei, Ling ;

Riffle, Lisa ;

Kaur, Gurmeet ;

Hill, G. Craig ;

Jacobs, Paula M. ;

Tatum, James L. ;

Doroshow, James H. ;

Kalen, Joseph D. .

NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (04) :451-457

[6] Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer [J].

Brem, Rachel F. ;

Floerke, Angelique C. ;

Rapelyea, Jocelyn A. ;

Teal, Christine ;

Kelly, Tricia ;

Mathur, Vivek .

RADIOLOGY, 2008, 247 (03) :651-657

[7] Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: A comparative study [J].

Brem, Rachel F. ;

Fishman, Michael ;

Rapelyea, Jocelyn A. .

ACADEMIC RADIOLOGY, 2007, 14 (08) :945-950

[8] New approaches for imaging tumour responses to treatment [J].

Brindle, Kevin .

NATURE REVIEWS CANCER, 2008, 8 (02) :94-107

[9] FDG uptake in breast cancer:: correlation with biological and clinical prognostic parameters [J].

Buck, A ;

Schirrmeister, H ;

Kühn, T ;

Shen, CX ;

Kalker, T ;

Kotzerke, J ;

Dankerl, A ;

Glatting, G ;

Reske, S ;

Mattfeldt, T .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) :1317-1323

[10] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

← 1 2 3 4 5 6 7 8 →